Keyword Analysis & Research: arrakis therapeutics
Keyword Research: People who searched arrakis therapeutics also searched
Search Results related to arrakis therapeutics on Search Engine
-
Arrakis - Arrakis Therapeutics
https://arrakistx.com/
Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche JOIN THE EXPEDITION We are on a mission that takes fearlessness and resilience to pioneer new science, but we also make enjoying the journey as important as the destination.
DA: 86 PA: 74 MOZ Rank: 81
-
Expedition RNA - Arrakis - Arrakis Therapeutics
https://arrakistx.com/about/expedition-rna/
Arrakis has a simple but powerful vision: To extend small-molecule medicines into new realms of biology, unlocking that biology for medicine. Our approach builds on the existing sophisticated drug discovery toolkit developed for protein targets, which we are adapting and refocusing on discovering small-molecule compounds that act directly on RNA. We are pioneering new territory, […]
DA: 28 PA: 85 MOZ Rank: 67
-
Arrakis Therapeutics | LinkedIn
https://www.linkedin.com/company/arrakis-therapeutics
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. The company’s TRYST™ and PEARL-seq™ platforms identify new ...
DA: 14 PA: 53 MOZ Rank: 9
-
Arrakis Therapeutics Inc - Company Profile and News ...
https://www.bloomberg.com/profile/company/1491724D:US
Arrakis Therapeutics, Inc. operates as a pharmaceutical company. The Company discovers medicines for the treatment of cancer. Arrakis Therapeutics serves the healthcare sector in the United States.
DA: 22 PA: 3 MOZ Rank: 13
-
Arrakis Therapeutics | CipherBio
https://www.cipherbio.com/data-viz/organization/Arrakis%2BTherapeutics
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of small-molecule medicines that directly bind to and modify the biological function of RNA to treat disease. This new class of medicines, RNA-targeted small molecules (rSMs), can unlock the therapeutic potential of deeply researched, valuable targets that are not ...
DA: 17 PA: 54 MOZ Rank: 21
-
Arrakis Therapeutics Publishes Advanced Research Method To ...
https://finance.yahoo.com/news/arrakis-therapeutics-publishes-advanced-research-130000646.html
Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced the publication of data ...
DA: 13 PA: 25 MOZ Rank: 78
-
Arrakis Therapeutics Appoints Patrizio Renzetti as Vice ...
https://www.businesswire.com/news/home/20201119005323/en/Arrakis-Therapeutics-Appoints-Patrizio-Renzetti-as-Vice-President-of-Human-Resources
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small ...
DA: 69 PA: 22 MOZ Rank: 45
-
Roche partners with Arrakis Therapeutics to develop drugs ...
https://www.statnews.com/2020/04/08/roche-arrakis-partnership-rna-targeting/
L ast year, Arrakis Therapeutics announced early but important progress toward a drug-development goal long thought to be a biotech fantasy: the creation of oral medicines that can target RNA, the ...
DA: 54 PA: 90 MOZ Rank: 43
-
Amid a pandemic, Roche bets $190M on Arrakis and drugging ...
https://www.biopharmadive.com/news/arrakis-roche-deal-drugging-rna/575695/
Dive Brief: Roche will pay privately held Arrakis Therapeutics $190 million in a wide-ranging deal to co-develop small molecule drugs that target RNA molecules.; Cambridge, Massachusetts-based Arrakis will handle the early drug development work, after which Roche can license those that show promise and take the lead on clinical testing.
DA: 28 PA: 55 MOZ Rank: 50
-
Arrakis, Roche team up on RNA-targeting drugs in $190M ...
https://www.fiercebiotech.com/biotech/arrakis-roche-team-up-rna-targeting-drugs-190m-deal
Arrakis Therapeutics has been dodging pharma suitors since its early days, keeping its head down and “politely declining” advances “because we weren’t ready.” Now, the biotech has ...
DA: 18 PA: 97 MOZ Rank: 89
